	US 12,071,674 B2
	Nucleic acid probe set and nucleic acid lateral flow immunoassay having the same
Cheng-Che Liu, Taipei (TW); Po-Da Hong, Taipei (TW); Yi-Huei Huang, Taipei (TW); Kuan-Yi Yu, Taipei (TW); Shou-Ping Huang, Taipei (TW); Shou-Hung Tang, Taipei (TW); and Juin-Hong Cherng, Taipei (TW)
Assigned to National Defense Medical Center, Taipei (TW)
Filed by National Defense Medical Center, Taipei (TW)
Filed on Jun. 23, 2021, as Appl. No. 17/355,623.
Claims priority of application No. 110109507 (TW), filed on Mar. 17, 2021.
Prior Publication US 2022/0298588 A1, Sep. 22, 2022
Int. Cl. C12Q 1/6804 (2018.01); C12Q 1/6813 (2018.01); C12Q 1/70 (2006.01); G01N 33/53 (2006.01); B01L 3/00 (2006.01)

CPC C12Q 1/701 (2013.01) [C12Q 1/6804 (2013.01); C12Q 1/6813 (2013.01); C12Q 1/70 (2013.01); G01N 33/5308 (2013.01); B01L 3/5027 (2013.01); B01L 3/502715 (2013.01); G01N 2333/025 (2013.01)]

15 Claims

1. A nucleic acid probe set, comprising:

a capture probe, comprising a first nucleotide sequence that comprises at least 19 nucleotide bases and a combiner connected to one terminal base of the first nucleotide sequence; and

a detection probe, comprising a second nucleotide sequence that comprises at least 19 nucleotide bases and a label connected to one terminal base of the second nucleotide sequence;

wherein the first nucleotide sequence and the second nucleotide sequence

comprise a nucleotide sequence of 5′-GAAAGGAAGGTAAGTTGTTAAG-3′ (SEQ ID NO:8) and 5′-TATGTATGAATAGAGTCTTAGGT-3′ (SEQ ID NO:7), respectively, or vice versa.